Loading clinical trials...
Loading clinical trials...
Prospective, Non Randomized, Phase II Study on MK-3475 in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients.
Conditions
Interventions
Pembrolizumab
Locations
1
Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome, Italy
Start Date
April 26, 2021
Primary Completion Date
June 15, 2025
Completion Date
June 15, 2025
Last Updated
December 20, 2021
NCT03050268
NCT06257264
NCT06964009
NCT00539162
NCT06915025
NCT06710548
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions